A rating of 78 puts Aclaris Therapeutics Inc (ACRS) near the top of the Biotechnology industry according to InvestorsObserver. Aclaris Therapeutics Inc's score of 78 means it scores higher than 78% of stocks in the industry. Aclaris Therapeutics Inc also received an overall rating of 63, putting it above 63% of all stocks. Biotechnology is ranked 29 out of the 148 industries.
What do These Ratings Mean?
Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 63 would rank higher than 63 percent of all stocks.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.
What's Happening With Aclaris Therapeutics Inc Stock Today?
Aclaris Therapeutics Inc (ACRS) stock has gained 9.93% while the S&P 500 has fallen -0.12% as of 10:24 AM on Tuesday, Dec 22. ACRS has risen $0.60 from the previous closing price of $6.04 on volume of 654,019 shares. Over the past year the S&P 500 is up 14.47% while ACRS has risen 264.84%. ACRS lost -$1.35 per share the over the last 12 months.